Martin Shkreli calls out industry price hikes with new 'Pharma Skeletons' website

Martin Shkreli, former CEO of Turing Pharmaceuticals, is targeting the drug industry with a new website highlighting the major issues of individual drugmakers, reports STAT News.

Industry lobby group Pharmaceutical Research and Manufacturers of America launched a new ad campaign Monday designed to improve the industry's public image and intentionally separate itself from Mr. Shkreli following widespread criticism over high drug prices.

Hours after PhRMA introduced the campaign, Mr. Shkreli launched PharmaSkeletons.com, a website berating the industry group and calling out individual drugmakers for their own alleged transgressions.

Mr. Shkreli, infamous for raising the price of a drug by 5,000 percent overnight, argues that his own price hike is nothing compared to the inappropriate or unethical actions of other drugmakers.

"Look in the mirror," Shkreli writes on the site. "Pharma is a wonderful industry that does great things, but trying to throw me under the bus is foolish."

Here are five comments Mr. Shkreli made about drugmakers on his website.

1. On Allergan: "Allergan pretends 10 percent price increases make sense in a no-inflation environment. Just assume no one can do math. A big price increase on a small product is worse than small increases on big products, right?"

2. On Marathon Pharmaceuticals: "These guys invented price increases. I literally learned it from them."

3. On Bayer: "We raise prices on drugs by 100 percent-plus but no one notices."

4. On Amgen: "No price increases here! No scientists either! Just lawyers….The company hasn't had a science-oriented CEO in decades. Their R&D productivity is pathetic."

5. On Mallinckrodt Pharmaceuticals: "Really? Acthar [gel's] 65,000 percent price increase represents your values but Turing doesn't?"

Mr. Shkreli told STAT that he plans to keep updating the site. "I will be adding details continuously," he said via email.

More articles on supply chain:

Roche earns priority review status for arthritis drug
Trump seeks to bring supply chains back to US with 'major' border tax: 5 things to know
Florida health officials warn of potential drug shortages following McKesson suspension

 

 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.